Insider Transactions Reported by 19 Insiders of Immunovant, Inc.

Symbol: IMVT on Nasdaq
Location: Durham, NC

Quick Takeaways

IMVT - Immunovant, Inc. has 19 insiders with reported activity on this page.
Net insider value flow over the last year: +$346,231,431.
Recent transaction rows are available for direct filing-level review.

What Changed

Buy value: $349,999,986; sell value: $3,768,554.
Net share flow: +16,514,080.

Why This Matters

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Source Evidence

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Net insider flow leans to buying over the last 12 months. Net value: +$346,231,431.

Buys

$349,999,986

Shares: 16,666,666

Insiders: 1

Sells

$3,768,555

Shares: 152,586

Insiders: 8

Net

+$346,231,431

Shares: +16,514,080

Insiders: -7

Window (months)	Buy shares	Sell shares	Buy $	Sell $	Net $
0-3	0	72,877	$0	$1,945,853	-$1,945,853
3-6	16,666,666	63,868	$349,999,986	$1,538,410	+$348,461,576
6-9	0	7,972	$0	$143,908	-$143,908
9-12	0	7,869	$0	$140,384	-$140,384

Immunovant, Inc. executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
Roivant Sciences Ltd.	Director, 10%+ Owner	$2,379,657,147	+$349,999,986	+17%	Filing P/S	12 Dec 2025
Frank Torti	Director	$25,068,718			Median	07 Apr 2026
Peter Salzmann	Chief Executive Officer, Director	$17,543,264			Filing P/S	16 Apr 2025
Julia G. Butchko	Chief Development Officer	$14,251,795			Filing P/S	21 Aug 2024
Mark S. Levine	Chief Legal Officer	$8,124,353			Filing P/S	20 Nov 2024
Jay S. Stout	Chief Technology Officer	$7,454,909	-$567,416	-7.1%	Filing P/S	23 Apr 2026
William L. Macias	Chief Medical Officer	$7,454,384			Filing P/S	19 Feb 2025
Tiago Girao	Chief Financial Officer	$7,333,793	-$763,011	-9.4%	Filing P/S	23 Apr 2026
Eric Venker	Chief Executive Officer, Director	$6,254,909	-$342,854	-5.2%	Median	07 Apr 2026
Melanie Gloria	Chief Operating Officer	$6,088,862	-$604,988	-9%	Filing P/S	08 Apr 2026
Eva Renee Barnett	Chief Financial Officer	$5,907,965			Filing P/S	16 Apr 2025
Christopher van Tuyl	Chief Legal Officer	$4,549,625	-$491,028	-9.7%	Filing P/S	08 Apr 2026
Michael Geffner	Chief Medical Officer	$4,147,740	-$133,403	-3.1%	Filing P/S	22 Oct 2025
Atul Pande	Director	$3,396,329			Median	07 Apr 2026
Douglas J. Hughes	Director	$3,344,713	-$348,665	-9.4%	Median	07 Apr 2026
George Migausky V	Director	$2,739,530			Mixed	01 Apr 2025
Andrew J. Fromkin	Director	$2,477,293	-$517,189	-17%	Median	07 Apr 2026
Jake Bauer	Director	$966,157			Median	07 Apr 2026
Robert Graham Susman	Director	$966,157			Median	07 Apr 2026

Top shareholders of Immunovant, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Roivant Sciences Ltd.	13D/G 3/4/5	Director, 10%+ Owner	56%	113,327,007	$2,812,776,314	+$413,666,650	12 Dec 2025	13D/G 3/4/5
FMR LLC	13F 13D/G	Company	8.4% from 13D/G	16,990,754	$431,904,967	—	31 Dec 2025	13F 13D/G
Deep Track Capital, LP	13F 13D/G	Company	5.6% from 13D/G	11,526,971	$293,015,603	—	31 Dec 2025	13F 13D/G
VANGUARD GROUP INC	13F	Company	3.8%	7,779,314	$197,750,162	—	31 Dec 2025	13F
BlackRock, Inc.	13F	Company	3%	6,058,216	$153,999,851	—	31 Dec 2025	13F
ARMISTICE CAPITAL, LLC	13F	Company	2.8%	5,747,155	$146,092,680	—	31 Dec 2025	13F
BAKER BROS. ADVISORS LP	13F	Company	2.7%	5,457,881	$138,739,335	—	31 Dec 2025	13F
T. Rowe Price Investment Management, Inc.	13F	Company	2.5%	5,060,399	$128,636,000	—	31 Dec 2025	13F
MORGAN STANLEY	13F	Company	2.4%	4,846,385	$123,195,151	—	31 Dec 2025	13F
STATE STREET CORP	13F	Company	1.9%	3,786,926	$96,263,659	—	31 Dec 2025	13F
RTW INVESTMENTS, LP	13F	Company	1.6%	3,177,850	$80,780,947	—	31 Dec 2025	13F
Two Seas Capital LP	13F	Company	1.4%	2,866,962	$72,878,174	—	31 Dec 2025	13F
Alpine Global Management, LLC	13F	Company	1.3%	2,626,692	$66,770,511	—	31 Dec 2025	13F
ADAR1 Capital Management, LLC	13F	Company	1.2%	2,480,968	$63,066,207	—	31 Dec 2025	13F
Point72 Asset Management, L.P.	13F	Company	0.99%	2,000,000	$50,840,000	—	31 Dec 2025	13F
PERCEPTIVE ADVISORS LLC	13F	Company	0.98%	1,994,890	$50,710,104	—	31 Dec 2025	13F
Woodline Partners LP	13F	Company	0.97%	1,975,869	$50,226,590	—	31 Dec 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.92%	1,857,532	$47,226,549	—	31 Dec 2025	13F
TCG Crossover Management, LLC	13F	Company	0.82%	1,660,933	$42,220,917	—	31 Dec 2025	13F
Logos Global Management LP	13F	Company	0.68%	1,375,000	$34,952,500	—	31 Dec 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.64%	1,296,008	$32,944,523	—	31 Dec 2025	13F
Aberdeen Group plc	13F	Company	0.58%	1,184,122	$30,100,381	—	31 Dec 2025	13F
Soleus Capital Management, L.P.	13F	Company	0.55%	1,110,000	$28,216,200	—	31 Dec 2025	13F
Frank Torti	3/4/5	Director	— mixed-class rows	1,097,553 mixed-class rows	$25,068,718	—	07 Apr 2026	3/4/5
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	0.44%	893,056	$22,703,000	—	31 Dec 2025	13F
ADAGE CAPITAL PARTNERS GP, L.L.C.	13F	Company	0.43%	863,000	$21,937,460	—	31 Dec 2025	13F
GREAT POINT PARTNERS LLC	13F	Company	0.37%	750,000	$19,065,000	—	31 Dec 2025	13F
UBS Group AG	13F	Company	0.36%	732,386	$18,617,252	—	31 Dec 2025	13F
JENNISON ASSOCIATES LLC	13F	Company	0.35%	700,464	$17,805,795	—	31 Dec 2025	13F
Peter Salzmann	3/4/5	Chief Executive Officer, Director	— mixed-class rows	1,552,586 mixed-class rows	$17,543,264	—	16 Apr 2025	3/4/5
S.c.a. Candriam	13F	Individual	0.34%	680,372	$17,295,793	—	31 Dec 2025	13F
STEMPOINT CAPITAL LP	13F	Company	0.32%	644,959	$16,394,858	—	31 Dec 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.32%	642,974	$16,344,399	—	31 Dec 2025	13F
NORTHERN TRUST CORP	13F	Company	0.28%	566,148	$14,391,481	—	31 Dec 2025	13F
Julia G. Butchko	3/4/5	Chief Development Officer	— mixed-class rows	509,682 mixed-class rows	$14,251,795	—	21 Aug 2024	3/4/5
Connor, Clark & Lunn Investment Management Ltd.	13F	Company	0.23%	467,469	$11,883,062	—	31 Dec 2025	13F
Pictet Asset Management Holding SA	13F	Company	0.19%	380,842	$9,681,004	—	31 Dec 2025	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0.17%	353,056	$8,974,684	—	31 Dec 2025	13F
Mark S. Levine	3/4/5	Chief Legal Officer	— mixed-class rows	387,951 mixed-class rows	$8,124,353	—	20 Nov 2024	3/4/5
BANK OF AMERICA CORP /DE/	13F	Company	0.15%	313,481	$7,968,686	—	31 Dec 2025	13F
Jay S. Stout	3/4/5	Chief Technology Officer	— mixed-class rows	348,536 mixed-class rows	$7,454,909	-$567,416	23 Apr 2026	3/4/5
William L. Macias	3/4/5	Chief Medical Officer	— mixed-class rows	426,076 mixed-class rows	$7,454,384	—	19 Feb 2025	3/4/5
SUPERSTRING CAPITAL MANAGEMENT LP	13F	Company	0.14%	288,677	$7,338,169	—	31 Dec 2025	13F
Tiago Girao	3/4/5	Chief Financial Officer	— mixed-class rows	341,598 mixed-class rows	$7,333,793	-$763,011	23 Apr 2026	3/4/5
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.13%	259,117	$6,586,754	—	31 Dec 2025	13F
Eric Venker	3/4/5	Chief Executive Officer, Director	— mixed-class rows	1,694,106 mixed-class rows	$6,254,909	-$342,854	07 Apr 2026	3/4/5
Prosight Management, LP	13F	Company	0.12%	243,404	$6,187,330	—	31 Dec 2025	13F
Trails Edge Capital Partners, LP	13F	Company	0.12%	240,165	$6,104,994	—	31 Dec 2025	13F
Melanie Gloria	3/4/5	Chief Operating Officer	— mixed-class rows	366,285 mixed-class rows	$6,088,862	-$604,988	08 Apr 2026	3/4/5
Eva Renee Barnett	3/4/5	Chief Financial Officer	— mixed-class rows	521,954 mixed-class rows	$5,907,965	—	16 Apr 2025	3/4/5

Recent Insider Transactions by Companies or Individuals for Immunovant, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership
Tiago Girao	IMVT	Common Stock	Sale	-9.42%	$763,011	$29.62	-25,760	247,596	23 Apr 2026	Direct
Jay S. Stout	IMVT	Common Stock	Sale	-1.08%	$81,573	$29.62	-2,754	251,685	23 Apr 2026	Direct
Christopher van Tuyl	IMVT	Common Stock	Sale	-2.74%	$128,247	$24.83	-5,165	183,231	08 Apr 2026	Direct
Melanie Gloria	IMVT	Common Stock	Sale	-3.43%	$216,567	$24.83	-8,722	245,222	08 Apr 2026	Direct
Jay S. Stout	IMVT	Common Stock	Sale	-3.83%	$251,578	$24.83	-10,132	254,439	08 Apr 2026	Direct
Frank Torti	IMVT	Common Stock	Award	20.9%			174,189	1,009,228	07 Apr 2026	Direct
Frank Torti	IMVT	Stock Option (right to buy)	Award				88,325	88,325	07 Apr 2026	Direct
Andrew J. Fromkin	IMVT	Common Stock	Award	16.2%			13,880	99,732	07 Apr 2026	Direct
Andrew J. Fromkin	IMVT	Stock Option (right to buy)	Award				7,061	7,061	07 Apr 2026	Direct
Douglas J. Hughes	IMVT	Common Stock	Award	11.5%			13,880	134,653	07 Apr 2026	Direct
Douglas J. Hughes	IMVT	Stock Option (right to buy)	Award				7,061	7,061	07 Apr 2026	Direct
Atul Pande	IMVT	Common Stock	Award	13.5%			13,880	116,731	07 Apr 2026	Direct
Atul Pande	IMVT	Stock Option (right to buy)	Award				7,061	7,061	07 Apr 2026	Direct
Jake Bauer	IMVT	Common Stock	Award	55.5%			13,880	38,896	07 Apr 2026	Direct
Jake Bauer	IMVT	Stock Option (right to buy)	Award				7,061	7,061	07 Apr 2026	Direct
Robert Graham Susman	IMVT	Common Stock	Award	55.5%			13,880	38,896	07 Apr 2026	Direct
Robert Graham Susman	IMVT	Stock Option (right to buy)	Award				7,061	7,061	07 Apr 2026	Direct
Melanie Gloria	IMVT	Common Stock	Award	49.1%			83,671	253,944	07 Apr 2026	Direct
Melanie Gloria	IMVT	Stock Option (right to buy)	Award				121,063	121,063	07 Apr 2026	Direct
Jay S. Stout	IMVT	Common Stock	Award	33.9%			66,937	264,571	07 Apr 2026	Direct
Jay S. Stout	IMVT	Stock Option (right to buy)	Award				96,851	96,851	07 Apr 2026	Direct
Christopher van Tuyl	IMVT	Common Stock	Award	28.1%			41,343	188,396	07 Apr 2026	Direct
Christopher van Tuyl	IMVT	Stock Option (right to buy)	Award				59,820	59,820	07 Apr 2026	Direct
Eric Venker	IMVT	Common Stock	Award	1187.3%			232,252	251,813	07 Apr 2026	Direct
Eric Venker	IMVT	Stock Option (right to buy)	Award				336,043	336,043	07 Apr 2026	Direct
Tiago Girao	IMVT	Common Stock	Award	31.2%			64,968	273,356	07 Apr 2026	Direct
Tiago Girao	IMVT	Stock Option (right to buy)	Award				94,002	94,002	07 Apr 2026	Direct
Eric Venker	IMVT	Common Stock	Sale	-42.1%	$342,854	$24.10	-14,229	19,561	02 Apr 2026	Direct
Eric Venker	IMVT	Common Stock	Disposed to Issuer	-90.8%			-334,960	33,790	01 Apr 2026	Direct
Eric Venker	IMVT	Common Stock	Options Exercise				368,750	368,750	01 Apr 2026	Direct
Eric Venker	IMVT	Capped Value Appreciation Rights	Options Exercise	-25%			-368,750	1,106,250	01 Apr 2026	Direct
Christopher van Tuyl	IMVT	Common Stock	Sale	-1.92%	$71,839	$24.97	-2,877	147,053	18 Mar 2026	Direct
Melanie Gloria	IMVT	Common Stock	Sale	-1.87%	$90,184	$27.85	-3,238	170,273	25 Feb 2026	Direct
Jay S. Stout	IMVT	Common Stock	Sale	-0.99%	$51,461	$26.03	-1,977	197,634	21 Jan 2026	Direct
Jay S. Stout	IMVT	Common Stock	Sale	-0.6%	$31,914	$26.53	-1,203	199,611	07 Jan 2026	Direct
Christopher van Tuyl	IMVT	Common Stock	Sale	-6.73%	$290,943	$26.91	-10,813	149,930	18 Dec 2025	Direct
Roivant Sciences Ltd.	IMVT	Common Stock, $0.0001 par value per share	Purchase	17.2%	$349,999,986	$21.00	16,666,666	113,317,007	12 Dec 2025	Direct
Andrew J. Fromkin	IMVT	Common Stock	Sale	-20.6%	$517,189	$23.25	-22,249	85,852	01 Dec 2025	Direct
Douglas J. Hughes	IMVT	Common Stock	Sale	-11%	$348,665	$23.24	-15,000	120,773	01 Dec 2025	Direct
Melanie Gloria	IMVT	Common Stock	Sale	-6.78%	$298,237	$23.62	-12,626	173,511	20 Nov 2025	Direct
Michael Geffner	IMVT	Common Stock	Sale	-1.18%	$49,383	$19.03	-2,595	217,958	22 Oct 2025	Direct
Jay S. Stout	IMVT	Common Stock	Sale	-1.24%	$47,956	$19.03	-2,520	200,814	22 Oct 2025	Direct
Michael Geffner	IMVT	Common Stock	Sale	-0.57%	$20,734	$16.30	-1,272	220,553	08 Oct 2025	Direct
Jay S. Stout	IMVT	Common Stock	Sale	-0.77%	$25,836	$16.30	-1,585	203,334	08 Oct 2025	Direct
Eric Venker	IMVT	Capped Value Appreciation Rights	Award				1,475,000	1,475,000	28 Jul 2025	Direct
Eric Venker	IMVT	Stock Option (right to buy)	Award				1,489,900	1,300,000	28 Jul 2025	Direct
Jay S. Stout	IMVT	Common Stock	Sale	-1.35%	$50,911	$18.15	-2,805	204,919	23 Jul 2025	Direct
Michael Geffner	IMVT	Common Stock	Sale	-1.06%	$43,288	$18.15	-2,385	221,825	23 Jul 2025	Direct
Michael Geffner	IMVT	Common Stock	Sale	-0.51%	$19,998	$17.24	-1,160	224,210	09 Jul 2025	Direct
Jay S. Stout	IMVT	Common Stock	Sale	-0.73%	$26,188	$17.24	-1,519	207,724	09 Jul 2025	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.